The company's system involves an ocular implant that continuously produces therapeutic proteins to the eye for over two years. This therapy can be easily reversed by removing the implant, providing enhanced treatment options for physicians. Neurotech Pharmaceuticals focuses on developing transformative therapies for chronic eye diseases using its drug delivery platform called Encapsulated Cell Therapy (ECT). Founded in 2000 and based in Cumberland, Rhode Island, the company aims to address significant unmet medical needs in the ophthalmology market, particularly for chronic retinal diseases. Neurotech Pharmaceuticals offers MacTel treatment solutions, conducts MacTel clinical trials, and provides MacTel Implant Encapsulated Cell Therapy.